| axSpA (n = 325) | AS (n = 178) | nr-axSpA (n = 147) |
---|---|---|---|
Demographic characteristics | Â | ||
  Age, yr | 39.6 ± 11.9 | 41.5 ± 11.6 | 37.4 ± 11.8 |
  Sex, % male | 61.5 | 72.5 | 48.3 |
  Race, % white | 90.2 | 89.3 | 91.2 |
Disease characteristics | Â | ||
  Time from axSpA diagnosisb (yr), median (min–max) | 3.9 (0.0 to 37.9) | 5.5 (0.2 to 37.9) | 2.5 (0.0 to 32.2) |
  Symptom duration (yr), median (min–max) | 7.7 (0.3 to 50.9) | 9.1 (0.3 to 50.9) | 5.5 (0.3 to 41.5) |
  CRPc (mg/L), median (min–max) | 13.9 (0.1 to 174.8) | 14.3 (0.1 to 174.8) | 11.9 (0.1 to 156.2) |
  Positive for HLA-B27, n (%) | 255 (78.5) | 145 (81.5) | 110 (74.8) |
  BASDAI | 6.5 ± 1.6 | 6.4 ± 1.6 | 6.5 ± 1.5 |
  BASFI | 5.4 ± 2.2 | 5.7 ± 2.2 | 4.9 ± 2.3 |
  BASMI | 3.8 ± 1.7 | 4.4 ± 1.7 | 3.2 ± 1.5 |
  ASDAS | 3.8 ± 1.0 | 3.9 ± 0.9 | 3.7 ± 1.0 |
  Total spine paind | 7.0 ± 1.9 | 7.1 ± 1.9 | 7.0 ± 1.9 |
  Nocturnal spine paind | 6.9 ± 2.3 | 6.9 ± 2.2 | 6.9 ± 2.5 |
Prior TNF inhibitor exposure, % | 16.0 | 20.2 | 10.9 |
Health-related quality of life | |||
  Fatigue NRSd | 6.7 ± 1.9 | 6.6 ± 2.0 | 6.7 ± 1.8 |
  SF-36 MCSd | 40.5 ± 12.1 | 40.9 ± 12.0 | 40.0 ± 12.3 |
  SF-36 PCSd | 32.5 ± 7.5 | 32.0 ± 7.3 | 33.1 ± 7.8 |
  ASQoLd | 11.8 ± 4.3 | 11.8 ± 4.3 | 11.7 ± 4.3 |
  EQ-5D VAS | 48.3 ± 19.4 | 47.3 ± 18.5 | 49.4 ± 20.4 |